FDA Extends Review Deadline For Ilex' Clofarabine
This article was originally published in The Pink Sheet Daily
Executive Summary
Ilex submits data on 14 additional patients with acute lymphoblastic and acute myeloid leukemia to FDA, extending the user fee date by three months to Dec. 30. The company completed the original rolling NDA March 29.
You may also be interested in...
Ilex Clolar Gets Cmte. Nod On Accelerated Approval For ALL, But Not AML
Committee concludes that unconfirmed response can be considered useful for evaluating the drug’s effectiveness. FDA’s Pazdur voices concern to committee that Ilex may not have shown “due diligence” in initiating confirmatory trials.
Ilex Clolar Gets Cmte. Nod On Accelerated Approval For ALL, But Not AML
Committee concludes that unconfirmed response can be considered useful for evaluating the drug’s effectiveness. FDA’s Pazdur voices concern to committee that Ilex may not have shown “due diligence” in initiating confirmatory trials.
Ilex Clolar Efficacy Plus Transplant Success Is Likely Focus For Cmte. Review
One important issue will be the percentage of patients who have a successful transplant after responding to Clolar, briefing documents state. For patients who do not have a transplant, success depends on response duration, survival, toxicity and results achievable with other therapy. Study size is also likely topic for the committee.